Predictive modeling of Futile Recanalization: Endovascular treatment postoperative intravenous tirofiban use was associated with a lower rate of futile recanalization

Author:

Huang Jie1,Li Xiaoxiong2,Liang chunrong1,Li jinping2,Ma Lingqiu2,Ma Jinjin2,Hou Mingliang2,Li Ling1

Affiliation:

1. Army Medical University

2. The First Affiliated Hospital of Bengbu Medical College

Abstract

Abstract

Background Approximately 54% of patients with endovascular treatment will have futile recanalization, and the cause of this is not yet clear. Therefore, in this study, we aimed to build a risk prediction model to Identify the characteristics of such patients Methods Acute ischemic stroke participants from the Daping Hospital, endovascular treatment Project database were included. The predictors of futile recanalization were identified by single- and multi-factor analyses; then, the least absolute contraction and selection operator regression model (lasso) was used to optimize the characteristic variables. Finally, the prediction model was obtained by multi-factor logistic regression fitting, and a nomogram of futile recanalization risk after endovascular treatment of acute cerebral infarction was drawn. Receiver operating characteristic curve and C-index, calibration curve, and decision curve analysis were used to evaluate the discrimination, calibration degree, and clinical utility of the prediction model, respectively. Finally, a bootstrap algorithm was used to internally verify the C-index of the prediction model. Results Finally, predictive models showed an area under the curve of was 0.975 (90% CI: 0.953–0.997). Age (OR: 1.09, 95% CI: 1.00–1.19), the TOAST classification (OR: 0.10, 95% CI: 0.01–0.76), infection (OR: 390.18, 95% CI: 6.18–24656.32), the NIHSS score at discharge (OR: 1.40, 95% CI: 1.18–1.67), and tirofiban use (OR: 0.13, 95% CI: 0.02–0.94) were included in the model. Conclusions The clinical utility curve of DCA showed good clinical utility. our results support the argument that Endovascular treatment after intravenous tirofiban use was associated with a lower rate of futile recanalization.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3